Overview

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

Status:
RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Phase:
PHASE2
Details
Lead Sponsor:
Kiniksa Pharmaceuticals International, plc
Collaborator:
Kiniksa Pharmaceuticals, GmbH